Only 5 per cent of people infected with hepatitis B virus receive treatment

While 94 million people out of 292 million hepatitis B patients in 2016 were eligible for antiviral treatment, just 4.8 million got it, says a study

US sound and fury over drug prices

The US Senate is outraged by the rapacious pricing policy of drug firms but will it act to reform the system?

India, the antibiotic capital of the world

Antibiotics are often used to treat diarrhoea and upper respiratory tract infections, which can be reduced by improving sanitation and personal …

RCEP deal to make investors stronger, people weaker, says trade group

The deal will affect access to medicines and seeds by raising the standards of intellectual property rights, claims Forum of Trade Justice

Patients pay for high margins of pharma firms

Patients in India end up paying more for medicines and all kinds of treatment as prevailing conditions do not allow the market to function …

Drug research for children lags behind that for adults; WHO steps in to change it

Bacterial infections, such as pneumonia, neonatal sepsis, and gastrointestinal infections, are the leading causes of death among children worldwide

Online drug sale ban: Is there a need to regulate e-pharmacies?

Following an interim ban on online sale of medicines, many questions have been raised on the need for checks and balances

Indian pharma firms receive 34% of FDA warnings this year

These warnings were for misbranding, selling unapproved medicines and violating Current Good Management Practices

Beware of Japan's trade ambitions

Japan is pushing for higher levels of intellectual property protection that will cut access to affordable medicines

Lessons learnt tackling COVID-19 can be used in global AMR response: Report

Increased investment, availability and accessibility of health infrastructure and global cooperation key to tackling AMR, it says 

Rajasthan’s Right To Health Bill lacks teeth, say experts

Implementation timeframe, process missing from document

Drug pricing policies bent to favour pharma industry, allege health experts

Nearly 83 per cent medicines out of the ambit of price control policy, thus making them out of reach for most patients, say two recent reports